Submit a Letter to the Editor for:
Tetsushi Sadakata, Miwa Washida, Yoshimi Iwayama, Satoshi Shoji, Yumi Sato, Takeshi Ohkura, Ritsuko Katoh-Semba, Mizuho Nakajima, Yukiko Sekine, Mika Tanaka, Kazuhiko Nakamura, Yasuhide Iwata, Kenji J. Tsuchiya, Norio Mori, Sevilla D. Detera-Wadleigh, Hironobu Ichikawa, Shigeyoshi Itohara, Takeo Yoshikawa, Teiichi Furuichi
J Clin Invest. 2007;
117(4):931
doi:10.1172/JCI29031
Abstract |
Full text
|
PDF
|
Supplemental material
A
utism, characterized by profound impairment in social interactions and communicative skills, is the most common neurodevelopmental disorder, and its underlying molecular mechanisms remain unknown. Ca2+-dependent activator protein for secretion 2 (CADPS2; also known as CAPS2) mediates the exocytosis of dense-core vesicles, and the human CADPS2 is located within the autism susceptibility locus 1 on chromosome 7q. Here we show that Cadps2-knockout mice not only have impaired brain-derived neurotrophic factor release but also show autistic-like cellular and behavioral phenotypes. Moreover, we found an aberrant alternatively spliced CADPS2 mRNA that lacks exon 3 in some autistic patients. Exon 3 was shown to encode the dynactin 1–binding domain and affect axonal CADPS2 protein distribution. Our results suggest that a disturbance in CADPS2-mediated neurotrophin release contributes to autism susceptibility.
Guidelines:
The Editorial Board will only consider letters that we deem relevant and of interest to our readers. We will not post data that have not been subjected to peer review, nor will we post letters that are essentially a reiteration of another letter. All accepted letters will be posted on our website within one week of acceptance. The Editors reserve the right to edit any letter for length, content, and clarity. Authors of all accepted letters will be asked to preview any changes. Authors will be notified by e-mail if their letters were not accepted. As this is a final decision, no appeals will be considered.
Specific requirements: All letters must be 400 words or fewer. You may enter the letter as plain text or HTML, if you wish. The author's name and e-mail address are required, and will be posted with the letter. All possible conflicts of interest must be noted, even if they are not posted. If you wish to include a figure (keep in mind that non-peer-reviewed data will not be posted), please contact the editor directly at editors@the-jci.org.
